Cost per responder of biologic drugs used in the treatment of moderate-to-severe plaque psoriasis in France and Germany

References

• Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. IJMS. 2019;20(6):1475.
   Web of Science ®Google Scholar
• Pellegrini C, Orlandi A, Costanza G, et al. Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments. Shiku H, editor. PLOS One. 2017;12(8):e0183415.
   PubMed Web of Science ®Google Scholar
• Yang E, Beck K, Sanchez I, et al. The impact of genital psoriasis on quality of life: a systematic review. Psoriasis. 2018;8:41–47.
   PubMed Web of Science ®Google Scholar
• Parisi R, Symmons DPM, Griffiths CEM, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385.
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis. Lancet. 2021;397(10281):1301–1315.
   PubMed Web of Science ®Google Scholar
• Ortonne J, Chimenti S, Luger T, et al. Scalp psoriasis: European consensus on grading and treatment algorithm: scalp psoriasis: European consensus. J Eur Acad Dermatol Venereol. 2009;23(12):1435–1444.
   PubMed Web of Science ®Google Scholar
• Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590.
   PubMed Web of Science ®Google Scholar
• Damiani G, Bragazzi NL, Karimkhani Aksut C, et al. The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study. Front Med. 2021;8:743180.
   PubMed Web of Science ®Google Scholar
• Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol. 2012;132(3 Pt 1):556–562.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Bellinato F, Girolomoni G, et al. Pathogenesis of chronic plaque psoriasis and its intersection with cardio-metabolic comorbidities. Front Pharmacol. 2020;11:117.
   PubMed Web of Science ®Google Scholar
• Damiani G, Cazzaniga S, Conic RRZ, et al. Pruritus characteristics in a large italian cohort of psoriatic patients. J Eur Acad Dermatol Venereol. 2019;33(7):1316–1324.
   PubMed Web of Science ®Google Scholar
• Bhosle MJ, Kulkarni A, Feldman SR, et al. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006;4(1):35.
   PubMedGoogle Scholar
• Tribó M, Turroja M, Castaño-Vinyals G, et al. Patients with moderate to severe psoriasis associate with higher risk of depression and anxiety symptoms: results of a multivariate study of 300 Spanish individuals with psoriasis. Acta Derm Venereol. 2019;99(4):417–422.
   PubMed Web of Science ®Google Scholar
• Kowalewska B, Jankowiak B, Cybulski M, et al. Effect of disease severity on the quality of life and sense of stigmatization in psoriatics. Clin Cosmet Investig Dermatol. 2021;14:107–121.
   PubMed Web of Science ®Google Scholar
• Goff KL, Karimkhani C, Boyers LN, et al. The global burden of psoriatic skin disease. Br J Dermatol. 2015;172(6):1665–1668.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10.
   PubMed Web of Science ®Google Scholar
• Leonardi C, See K, Gallo G, et al. Psoriasis severity assessment combining physician and patient reported outcomes: the optimal psoriasis assessment tool. Dermatol Ther. 2021;11(4):1249–1263.
   Web of Science ®Google Scholar
• Kragballe K, van de Kerkhof PCM, Gordon KB. Unmet needs in the treatment of psoriasis. Eur J Dermatol. 2014;24(5):523–532.
   PubMed Web of Science ®Google Scholar
• Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane skin group, editor. Cochrane Database Syst Rev. 2020;1(1):CD011535. 10.1002/14651858.CD011535.pub2
   PubMedGoogle Scholar
• Sawyer LM, Cornic L, Levin LÅ, et al. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. J Eur Acad Dermatol Venereol. 2019;33(2):355–366.
   PubMed Web of Science ®Google Scholar
• Rønholt K, Iversen L. Old and new biological therapies for psoriasis. IJMS. 2017;18(11):2297.
   Web of Science ®Google Scholar
• Amatore F, Villani A ‐, Tauber M, et al. French guidelines on the use of systemic treatments for moderate‐to‐severe psoriasis in adults. J Eur Acad Dermatol Venereol. 2019;33(3):464–483.
   PubMed Web of Science ®Google Scholar
• Nast A, Altenburg A, Augustin M, et al. German S3‐guideline on the treatment of psoriasis vulgaris, adapted from EuroGuiDerm – part 1: treatment goals and treatment recommendations. J Dtsch Dermatol Ges. 2021;19(6):934.
   Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Camela Snr E, et al. Bimekizumab for the treatment of psoriasis: a review of the current knowledge. Psoriasis. 2022;12:127–137.
   PubMed Web of Science ®Google Scholar
• Yasmeen N, Sawyer LM, Malottki K, et al. Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year. J Dermatolog Treat. 2022;33(1):204–218.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Soliman AM, Betts KA, et al. Long-term benefit–risk profiles of treatments for moderate-to-severe plaque psoriasis: a network meta-analysis. Dermatol Ther. 2022;12(1):167–184.
   PubMed Web of Science ®Google Scholar
• Thaci D, Piaserico S, Warren RB, et al. Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). Br J Dermatol. 2021;185(2):323–334.
   PubMed Web of Science ®Google Scholar
• Armstrong A, Fahrbach K, Leonardi C, et al. Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: a systematic literature review and a network meta-analysis. Dermatol Ther. 2022;12(8):1777–1792.
   PubMed Web of Science ®Google Scholar
• ABDATA Pharma-Daten-Service. Pharmaceutical manufacturer prices in Germany. 2023.
   Google Scholar
• National Health Insurance Agency (AMELI). Pharmaceutical retail prices in France. 2023.
   Google Scholar
• European Medicines Agency. Taltz: summary of product characteristics [Internet]. 2020 [cited 2022 Dec 11]. Available from: https://www.ema.europa.eu/en/documents/product-information/taltz-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency. Bimzelx®: summary of product characteristics [Internet]. 2022 [cited 2022 Dec 11]. Available from: https://www.ema.europa.eu/en/documents/product-information/bimzelx-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency. Cosentyx®: summary of product characteristics [Internet]. 2022 [cited 2022 Dec 11]. Available from: https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency. Enbrel®: summary of product characteristics [Internet]. 2022 [cited 2022 Dec 11]. Available from: https://www.ema.europa.eu/en/documents/product-information/enbrel-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency. Hulio®: summary of product characteristics [Internet]. 2022 [cited 2022 Dec 11]. Available from: https://www.ema.europa.eu/en/documents/product-information/hulio-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency. Kyntheum®: summary of product characteristics [Internet]. 2022 [cited 2022 Dec 11]. Available from: https://www.ema.europa.eu/en/documents/product-information/kyntheum-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency. SkyriziTM: summary of product characteristics [Internet]. 2022 [cited 2022 Dec 11]. Available from: https://www.ema.europa.eu/en/documents/product-information/skyrizi-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency. Stelara®: summary of product characteristics [Internet]. 2022 [cited 2022 Dec 11]. Available from: https://www.ema.europa.eu/en/documents/product-information/stelara-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency. Tremfya®: summary of product characteristics [Internet]. 2022 [cited 2022 Dec 11]. Available from: https://www.ema.europa.eu/en/documents/product-information/tremfya-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency. Cimzia®: summary of product characteristics [Internet]. 2022 [cited 2022 Dec 13]. Available from: https://www.ema.europa.eu/en/documents/product-information/cimzia-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency. Ilumetri®: summary of product characteristics [Internet]. 2022 [cited 2022 Dec 13]. Available from: https://www.ema.europa.eu/en/documents/product-information/ilumetri-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency. Zessly®: summary of product characteristics [Internet]. 2022 [cited 2022 Dec 13]. Available from: https://www.ema.europa.eu/en/documents/product-information/zessly-epar-product-information_en.pdf
   Google Scholar
• Egeberg A, Freilich J, Stelmaszuk MN, et al. Real-world dose adjustments of biologic treatments in psoriasis and their economic impact – a Swedish National Population Study. Clin Exp Dermatol. 2022;47(11):1968–1975.
   PubMed Web of Science ®Google Scholar
• Torres T, Puig L, Vender R, et al. Drug survival of interleukin (IL)‑17 and IL‑23 inhibitors for the treatment of psoriasis: a retrospective multi‑country, multicentric cohort study. Am J Clin Dermatol. 2022;23(6):891–904.
   PubMed Web of Science ®Google Scholar
• Augustin M, Wirth D, Mahlich J, et al. Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany. J Dermatolog Treat. 2022;33(2):976–982.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Danø A, Pedersen MH, et al. Modeling the optimal sequence of biologic therapies in plaque psoriasis in Spain. J Med Econ. 2021;24(1):1134–1142.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Rastogi S, Lin J. Effect of prior biologic use on cost-effectiveness of brodalumab vs. Ustekinumab for treatment of moderate-to-severe psoriasis in the United States. Dermatol Ther. 2018;8(3):441–453.
   Web of Science ®Google Scholar
• Al Sawah S, Foster SA, Burge R, et al. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis. J Med Econ. 2017;20(12):1224–1230.
   PubMed Web of Science ®Google Scholar
• Ravasio R, Antonelli S, Maiorino A, et al. Cost per responder for ixekizumab and other biologic drugs approved for the treatment of moderate-to-severe plaque psoriasis in Italy. Glob Reg Health Technol Assess. 2019;2019(8):228424031882228.
   Google Scholar
• Sbidian E, Mezzarobba M, Weill A, et al. Persistence of treatment with biologics for patients with psoriasis: a real‐world analysis of 16 545 biologic‐naïve patients from the french national health insurance database (SNIIRAM). Br J Dermatol. 2019;180(1):86–93.
   PubMed Web of Science ®Google Scholar
• Torres T, Puig L, Vender R, et al. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2021;22(4):567–579.
   PubMed Web of Science ®Google Scholar